Treatment of ER-negative breast cancer with an PDGF-CC inhibitor and anti-estrogen
Inventors
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Assignees
MemberParacrineParacrineParacrine develops regenerative therapies for chronic wound care, leveraging autologous cell-based treatments and real-time AI platforms to enhance healing precision, predictability, and efficiency. The company operates globally, focusing on scalable and cost-effective biological solutions that integrate advanced machine learning for improved patient outcomes.
Paracrine develops regenerative therapies for chronic wound care, leveraging autologous cell-based treatments and real-time AI platforms to enhance healing precision, predictability, and efficiency. The company operates globally, focusing on scalable and cost-effective biological solutions that integrate advanced machine learning for improved patient outcomes.
Abstract
The invention discloses that ER-negative breast cancers can be converted into ER positive breast cancers, such as to a breast cancer of luminal-like phenotype by treatment with anti-PDGF-CC antibodies. ER-positive breast cancers, including luminal-like breast cancers can be treated with anti-estrogen treatment. On this basis the invention discloses that surprisingly, ER-negative breast cancers can be treated with anti-estrogen treatment, if the treatment is combined with treatment with anti-PDGF-CC antibodies. Said treatment may for example be an adjuvant treatment, for example a treatment aiming at reducing the risk of relapse of a breast cancer after removal of the primary tumor by surgery.
Core Innovation
The invention provides methods and compositions using anti-PDGF-CC antibodies or PDGFR inhibitors with anti-estrogens to treat ER-negative breast cancer, including basal-like and triple-negative subtypes. The methods administer an anti-PDGF-CC antibody together with tamoxifen either simultaneously or sequentially in any order, and include kits-of-parts and formulation options including parenteral and oral administration. The methods encompass treatment of human individuals and aim to modify therapeutic responsiveness to endocrine agents.
The invention addresses endocrine resistance in ER-negative and basal-like breast cancers by inhibiting PDGF-CC signaling to convert or sensitize tumors to an ER-positive, luminal-like phenotype. Genetic deletion or pharmacologic neutralization of PDGF-CC reduces tumor growth, remodels stroma with less fibrosis and angiogenesis, upregulates luminal markers FOXA1 and ERα, and sensitizes previously ER-negative or basal-like tumors to endocrine therapies including tamoxifen and aromatase inhibitors such as letrozole.
The document describes a paracrine circuit in which tumor PDGF-CC activates cancer-associated fibroblasts to produce STC1, HGF and IGFBP3 that suppress luminal or ER expression, and states that blocking PDGF-CC reverses this suppression and restores anti-estrogen responsiveness. The methods include adjuvant and neoadjuvant use and provide a therapeutic strategy that reduces the risk of relapse after surgery.
Claims Coverage
One independent claim covers a method for treatment of triple negative breast cancer; five main inventive features are identified.
Combination anti-PDGF-CC antibody and tamoxifen therapy
Administering a therapeutically effective amount of an anti-PDGF-CC antibody together with tamoxifen to an individual to treat triple negative breast cancer.
Treatment of triple negative breast cancer characterized by absence of estrogen receptors
A method for treatment of triple negative breast cancer that is characterized by absence of estrogen receptors.
Simultaneous or sequential administration
Administering the anti-PDGF-CC antibody and tamoxifen either simultaneously or sequentially in any order.
Post-surgery treatment to reduce relapse risk
Wherein the breast cancer in the individual has been treated by surgery, and wherein the treatment reduces the risk of relapse.
Therapeutically effective amount to a human individual
Administering a therapeutically effective amount to an individual, wherein the individual is a human being.
The independent claim defines a combination regimen pairing an anti-PDGF-CC antibody with tamoxifen for treatment of ER-negative, triple negative breast cancer, permits simultaneous or sequential dosing in any order, specifies post-surgical use to reduce relapse risk, and requires administration of a therapeutically effective amount to a human individual.
Stated Advantages
Reduces tumor growth.
Remodels stroma with less fibrosis and less angiogenesis.
Upregulates luminal markers FOXA1 and ERα and restores luminal/ER expression.
Converts or sensitizes ER-negative and triple-negative/basal-like tumors to an ER-positive/luminal-like phenotype enabling response to endocrine therapy, including tamoxifen and aromatase inhibitors.
Reduces the risk of relapse after surgery.
Documented Applications
Treatment of ER-negative breast cancer, including basal-like and triple-negative subtypes.
Conversion or sensitization of otherwise hormone-insensitive ER-negative and triple-negative/basal-like breast cancers to respond to endocrine therapy, including tamoxifen and aromatase inhibitors.
Adjuvant and neoadjuvant use for administration of the anti-PDGF-CC antibody or PDGF-R inhibitor together with an anti-estrogen.
Kits-of-parts comprising an anti-PDGF-CC antibody or PDGF-R inhibitor together with an anti-estrogen for use in the described methods.
Use of PDGFR inhibitors (for example imatinib) or anti-PDGF-CC antibodies in combination with anti-estrogens to achieve the therapeutic effects described.
Administration in the post-surgery setting to reduce risk of relapse.
Formulation options including parenteral and oral administration.
Interested in licensing this patent?